SynAct Pharma AB (SE:SYNACT)
:SYNACT
Top Page
SynAct Pharma AB
(SYNACT)
Select Model
Select Model
Rating:56Neutral
Price Target:
kr23.50
▼(-1.26% Downside)
Action:ReiteratedDate:12/30/25
The score is primarily constrained by weak financial performance (no revenue, ongoing losses, and negative free cash flow), partially offset by a low-leverage balance sheet and improving loss/cash-burn trends. Technicals are supportive with price above major moving averages and positive MACD, while valuation remains difficult to justify due to negative earnings and no dividend support.
Positive Factors
Leadership Confidence
The lock-up agreement by leadership signals strong confidence in SynAct's strategy and commitment to long-term value creation, which can enhance investor trust and stability.
Negative Factors
No Revenue Generation
The absence of revenue generation highlights SynAct's reliance on external funding, posing a risk to financial sustainability until successful commercialization of its products.
Read all positive and negative factors
Positive Factors
Negative Factors
Leadership Confidence
The lock-up agreement by leadership signals strong confidence in SynAct's strategy and commitment to long-term value creation, which can enhance investor trust and stability.
Read all positive factors
SynAct Pharma AB (SYNACT) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr966.34M
Dividend YieldN/A
Average Volume (3M)214.83K
Price to Earnings (P/E)―
Beta (1Y)0.33
Revenue GrowthN/A
EPS Growth48.14%
CountrySE
Employees6
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.43
Shares Outstanding53,330,242
10 Day Avg. Volume154,831
30 Day Avg. Volume214,829
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)1.66
Price to Sales (P/S)0.00
P/FCF Ratio-3.98
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.91
Revenue Forecast (FY)N/A
SynAct Pharma AB Business Overview & Revenue Model
Company Description
SynAct Pharma AB, through its subsidiary, SynAct Pharma ApS, develops medicines for acute deterioration in inflammatory diseases. The company is developing AP1189, a drug candidate for the treatment of rheumatoid arthritis and idiopathic membranou...
How the Company Makes Money
SynAct Pharma makes money primarily through the development and eventual commercialization of its pharmaceutical products. Revenue streams are expected to include licensing agreements, partnerships with larger pharmaceutical companies, and sales o...
SynAct Pharma AB Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
66
Positive
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | -617.00K | -778.00K | -1.06M | -88.00K | 0.00 |
| EBITDA | -103.55M | -15.40M | -222.70M | -105.71M | -76.62M | -30.90M |
| Net Income | -91.07M | -82.40M | -215.81M | -99.20M | -69.30M | -26.55M |
Balance Sheet | ||||||
| Total Assets | 243.59M | 270.52M | 228.02M | 142.60M | 38.37M | 21.59M |
| Cash, Cash Equivalents and Short-Term Investments | 68.89M | 61.21M | 62.40M | 108.25M | 24.00M | 14.55M |
| Total Debt | 1.54M | 1.88M | 637.00K | 2.06M | 3.09M | 0.00 |
| Total Liabilities | 47.18M | 56.35M | 51.83M | 16.08M | 17.50M | 5.72M |
| Stockholders Equity | 196.41M | 214.17M | 176.19M | 126.52M | 20.87M | 15.87M |
Cash Flow | ||||||
| Free Cash Flow | -41.90M | -89.20M | -100.18M | -117.56M | -65.00M | -33.24M |
| Operating Cash Flow | -41.90M | -89.20M | -100.18M | -117.56M | -65.00M | -33.24M |
| Investing Cash Flow | 0.00 | 0.00 | 370.00K | 27.00K | -6.00K | -93.00K |
| Financing Cash Flow | 40.13M | 87.41M | 53.98M | 200.71M | 74.32M | 44.72M |
SynAct Pharma AB Technical Analysis
Negative
23.80
Price Trends
19.04
Negative
20.34
Negative
20.40
Negative
Market Momentum
-0.24
Negative
46.97
Neutral
77.66
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:SYNACT, the sentiment is Negative. The current price of 23.8 is above the 20-day moving average (MA) of 17.72, above the 50-day MA of 19.04, and above the 200-day MA of 20.40, indicating a neutral trend. The MACD of -0.24 indicates Negative momentum. The RSI at 46.97 is Neutral, neither overbought nor oversold. The STOCH value of 77.66 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:SYNACT.
SynAct Pharma AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
59 Neutral | kr2.25B | 9.60 | 167.77% | ― | 2687.51% | ― | |
56 Neutral | kr966.34M | -10.42 | -58.41% | ― | ― | 48.14% | |
55 Neutral | kr992.95M | 7.07 | 81.19% | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | kr542.60M | -4.37 | ― | ― | 131.20% | 32.28% | |
44 Neutral | kr367.29M | -4.79 | -79.60% | ― | ― | 31.62% | |
42 Neutral | kr26.30M | -0.24 | -186.13% | ― | ― | 0.30% |
* Healthcare Sector Average
SE:SYNACT
SynAct Pharma AB
18.12
0.44
2.49%
SE:ONCO
Oncopeptides AB
1.40
-0.47
-25.07%
SE:SANION
Saniona AB
16.30
10.02
159.55%
SE:ACE
Ascelia Pharma AB
2.90
0.39
15.34%
SE:GUARD
Guard Therapeutics International AB
1.30
-10.60
-89.04%
SE:CANTA
Cantargia AB
3.99
2.69
207.23%
SynAct Pharma AB Corporate Events
SynAct Pharma Launches Phase 2 RESPIRE Trial of Resomelagon in Viral Respiratory Insufficiency
Jan 30, 2026
SynAct Pharma has initiated a Phase 2 randomized, double-blind, placebo-controlled multicenter study, RESPIRE (SynAct-CS009-RESPIRE), to evaluate resomelagon in 96 patients hospitalized with respiratory insufficiency due to viral infections such a...
SynAct Pharma Names Long-Serving Finance Executive as Interim CFO
Jan 19, 2026
SynAct Pharma has appointed long-serving finance executive Malin Wikstrand as interim Chief Financial Officer, effective 19 January 2026, following the departure of former CFO Björn Westberg. Wikstrand, who has been with the company since 201...
SynAct Pharma Launches Share Buyback to Optimize Capital Structure
Jan 9, 2026
SynAct Pharma AB’s board has approved a share buyback program on Nasdaq Stockholm, using a mandate from a November 2025 extraordinary general meeting, to return excess liquidity to shareholders and optimize the company’s capital struct...
SynAct Pharma Leadership Enters Lock-Up Ahead of Key Clinical Milestones
Dec 23, 2025
SynAct Pharma’s board and management have voluntarily signed lock-up agreements preventing them from selling or otherwise disposing of their shares and related securities between 1 January and 30 June 2026, allowing only customary exceptions...
SynAct Pharma Leadership Buys Shares as Key Rheumatoid Arthritis Milestone Nears
Dec 22, 2025
SynAct Pharma AB announced that its top leadership, including the CEO, CSO, CBO, and Chairman of the Board, have collectively acquired 12,028 shares in the company on Nasdaq Stockholm, signaling internal confidence in the firm’s prospects. M...
SynAct Pharma AB Appoints Nomination Committee for 2026 AGM
Dec 11, 2025
SynAct Pharma AB has announced the appointment of its Nomination Committee in preparation for the Annual General Meeting (AGM) 2026. The committee, comprising representatives from the three largest shareholders and the chairman of the Board, is ta...
SynAct Pharma to Attend J.P. Morgan Healthcare Conference for Strategic Engagements
Dec 10, 2025
SynAct Pharma announced its participation in the upcoming J.P. Morgan Healthcare Conference in San Francisco, where CEO Jeppe Øvlesen will engage with potential partners and investors. The conference presents a significant opportunity for Syn...
SynAct Pharma AB Implements New Share Option Program and Share Management Strategy
Nov 27, 2025
SynAct Pharma AB held an Extraordinary General Meeting where key resolutions were passed, including the implementation of an employee share option program and authorization for the Board to manage the acquisition and transfer of own shares. These ...
SynAct Pharma to Present at Redeye Autoimmune and Inflammatory Diseases Event
Nov 19, 2025
SynAct Pharma AB announced its participation in the Redeye Autoimmune and Inflammatory Diseases event in Stockholm, where the company’s Chief Business Officer, Mads Bjerregaard, will present updates on their lead compound, resomelagon. This ...
SynAct Pharma Advances Resomelagon Phase 2b Study for Rheumatoid Arthritis
Nov 3, 2025
SynAct Pharma AB has made significant progress in its Phase 2b ADVANCE study for Resomelagon, a treatment for Rheumatoid Arthritis, by randomizing 190 out of 240 patients. The study aims to evaluate the efficacy of Resomelagon in combination with ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.